A Hidden Form of Diabetes: Why GAD Antibody Testing Matters for Young Adults

Most people think of type 1 diabetes as a disease that develops quickly in children and teenagers. But there's another form of autoimmune diabetes that progresses much more slowly. It's called LADA—latent autoimmune diabetes in adults.

LADA shares a key feature with type 1 diabetes: the immune system attacks the insulin-producing beta cells in the pancreas. However, in LADA, this attack happens gradually, sometimes over years. Because of its slower onset and appearance in adults, LADA is frequently misclassified as type 2 diabetes, the most common form of diabetes.

This misdiagnosis matters. If someone has LADA but is treated as if they have type 2 diabetes, they may not receive the right management for their actual condition, potentially delaying necessary insulin therapy and other personalized care.

One reliable way to distinguish LADA from type 2 diabetes is to look for GAD antibodies—immune proteins that target glutamic acid decarboxylase, an enzyme in beta cells. The presence of these antibodies suggests autoimmune beta-cell destruction is happening.

In clinical practice, people with GAD antibody levels of 5 U/mL or higher are considered to have an autoimmune form of diabetes. However, antibody testing is not standard practice everywhere, particularly in some regions of the world. This means many people with LADA may go unrecognized.

Researchers from a tertiary care center in Northeast India conducted a retrospective study to investigate how common GAD antibody positivity is among young people with diabetes. They analyzed stored blood samples from 149 individuals diagnosed with diabetes before age 40, all part of an earlier research cohort called PHENOEINDY-2 that ran from 2017 to 2021.

Using standardized laboratory testing (ELISA), the team measured GAD antibody levels in each participant. The results showed a wide range of antibody levels across the group, from very low to quite high (0.26 to 109.15 U/mL). On average, the group had a mean GAD level of 3.17 U/mL, with a median of 1.07 U/mL, indicating that many participants had low antibody levels but some had substantially elevated ones.

This distribution—heavily skewed toward lower values with some notably high outliers—suggests that while autoimmune diabetes may be present in this young population, it is not uniformly distributed. It also highlights the importance of testing to identify which individuals have GAD antibodies.

In many parts of the world, GAD antibody testing is not routine for young people diagnosed with diabetes. This study from Northeast India helps document the prevalence of autoimmune markers in a population where such data had been limited.

Understanding how common GAD antibody positivity is in different regions helps raise awareness among healthcare providers about the possibility of LADA in younger patients. It can support the case for wider screening, especially when young adults present with features that don't fit neatly into a type 2 diabetes diagnosis.

For individuals and families affected by diabetes, this work reinforces an important message: if you or a family member were diagnosed with diabetes at a young age, asking your doctor about GAD antibody testing may help clarify what type of diabetes you have—and lead to more personalized, effective care.

Source: Cureus. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.